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Serum cystatin C-immunoglobulin high-molecular-weight com- results obtained for renal transplant patients are still
plexes in kidney and liver transplant patients. very limited [8] and even contradictory.
Background. It has been suggested recently that the glomer- Some authors found that serum cystatin C was a goodular filtration rate (GFR) in renal transplant patients is under-
marker for GFR in renal transplant patients, and that itestimated by serum cystatin C due to an impaired filtration of
was clearly superior to the commonly used serum creati-complexed cystatin C with immunoglobulins. Consequently,
serum cystatin C may not be a reliable marker of GFR in these nine [9–12]. However, others believe that cystatin C in
patients. Our study was designed to determine whether this these cases would lead to a significant underestimation
supposition is correct.
of the GFR [13–15] and, consequently, that it is not aMethods. In 87 serum samples from patients with various
reliable marker in patients after renal transplantationkidney diseases, 182 samples from renal transplant patients,
and 72 samples from liver transplant patients, the concentra- [15]. Boke¨nkamp et al, after rejecting other possible
tions of cystatin C and creatinine were determined, as well as causes (analytical interference of immunosuppressors,
the residual concentration of cystatin C after precipitation of metabolic changes caused by immunosuppression, and
macromolecules with polyethylene glycol (PEG; 6000 molecu-
tubulointerstitial damage leading to a back-leak of intactlar weight).
cystatin C into circulation), suggested that it was dueResults. The residual concentration of serum cystatin C after
precipitation with PEG in all cases was much higher (70 to to an impaired glomerular filtration of the complexed
100%) than that expected in the case of the existence of cystatin cystatin C with immunoglobulins [14]. The immunoglob-
C-immunoglobulin complexes. In the kidney and liver trans- ulins may form high molecular weight complexes withplant patients, there was no significant correlation between the
normal serum constituents [16, 17], and the demonstra-residual concentration of cystatin C and the postoperative time
tion of the existence of these circulatory complexes is of(r  0.098).
Conclusions. The results suggest that in renal or liver trans- obvious clinical interest.
plant patients there is no formation of high molecular weight Macromolecules are known to precipitate selectively
serum cystatin C-immunoglobulin complexes, regardless of the in concentrated solutions of polyethylene glycol (PEG).post-transplant period.
Our study examined the possible existence of cystatin
C-immunoglobulin serum complexes in kidney and liver
transplant patients via precipitation with PEG. This tech-Human cystatin C is a nonglycosylated basic low mo-
nique has been widely used in the case of other serumlecular weight protein (13.3 kD) that is produced by
protein molecules [18–22].all nucleated cells with a stable production rate, and
therefore, its blood concentration should be determined
mainly by the glomerular filtration rate (GFR) [1–3]. METHODS
Serum cystatin C appears to meet the requirements of One hundred eighty-two serum samples were analyzed
an ideal GFR marker [3] and has been suggested to be from 52 patients who had undergone kidney transplanta-
more suitable than serum creatinine [4–7]. However, the
tion (26 male and 26 female; mean age  SEM of 47.8 
1.97 years; range 19 to 72 years) and 71 serum samples
from 28 liver transplant patients (17 male and 11 female;Key words: glomerular filtration rate, polyethylene glycol 6000, marker
for GFR, creatinine, end-stage renal disease. mean age 53.6  2.04 years; range 35 to 67 years). We
also analyzed 87 samples from 66 patients (42 male and
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these patients underwent periodic hemodialysis, samples
were taken immediately beforehand. Similarly, 14 serum
samples were studied from patients with rheumatoid ar-
thritis (4 male and 10 female; mean age of 55.0  2.8
years; range 23 to 78 years).
Serum cystatin C was determined using a particle-
enhanced immunoturbidimetric assay [23] in a Cobas
Fara II Analyser (Roche Diagnostics, Basel, Switzer-
land) using reagents from Dako Diagnostics (Copenha-
gen, Denmark); the reference interval considered in our
laboratory was 0.6 to 1.4 mg/L. Investigation of cystatin
C-immunoglobulin complexes was carried out by deter-
mining the residual concentration of cystatin C after pre-
cipitation with PEG (molecular weight 6000), according
to the procedure described by Levitt and Ellis [18]. Se-
rum samples were mixed with equal volumes of 240 g/L
PEG solution (final concentration 120 g/L), incubated
at 37C for 10 minutes and centrifuged; the cystatin C
concentrations in the supernants were determined, and
Fig. 1. Residual concentrations of recombinant human cystatin C (),the relative residual concentrations, with respect to the
serum cystatin C (), IgA (), IgG (), and IgM () after precipitationsame samples mixed with equal volumes of water, were
with different concentrations of polyethylene glycol (PEG).
calculated. The possible analytical interference from
PEG on the cystatin C turbidimetric determination was
studied using a recombinant human cystatin C solution
(4.5 mg/L) supplied by Dako Diagnostics. Serum creati- patients. No statistically significant difference was found
nine was determined using a kinetic alkaline picrate between the different groups of patients studied. We
method, which significantly reduces the interference of also obtained an analogous interindividual variation for
non-creatinine chromogens, in an Advia 1650 Analyser the residual concentrations of cystatin C in the groups
(Bayer Diagnostics, Mu¨nchen, Germany). of patients with kidney disease (CV 7.3%), liver trans-
Statistical analysis of the data was carried out using plantation (CV  8.2%), and kidney transplantation
the Microsoft-Excel package (version 5.0). The Kolmo- (CV  8.2%). In the 14 patients with rheumatoid arthri-
gorov-Smirnov test was applied to check for normality. tis, with a concentration of serum cystatin C of 1.63 
Parametric tests were used when the data had a Gaussian 0.11 mg/L (range 1.0 to 2.1 mg/L), there was a mean
distribution (Student t test and Pearson correlation coef- residual concentration of this protein, after precipitation
ficient); otherwise, nonparametric tests were used (Wil- with PEG, of 82.5  2.9% (range 61 to 100%).
coxon test and Spearman correlation coefficient). The In the kidney and liver transplant patients, no signifi-
results are expressed as mean  SEM and median. Sig- cant correlation was found between the residual concen-
nificance was defined as a P value of less than 0.05. tration of cystatin C and post-transplant time (Fig. 2).
Likewise, a significant correlation between these vari-
ables was not achieved when the kidney (r  0.059)RESULTS
or liver (r0.109) transplant patients were considered
Figure 1 shows the results corresponding to the resid- separately.
ual concentrations of recombinant human cystatin C,
serum cystatin C, and immunoglobulins A, G, and M,
DISCUSSIONafter precipitation with different final concentrations of
PEG (0 to 190 g/L) by means of the general procedure Precipitation with PEG has been shown to be a valid
screening test to detect serum immunoglobulin com-indicated in the Methods section. The results indicated
for serum cystatin C and immunoglobulins are the aver- plexes with several enzyme proteins [18–21] and prolac-
tin [22]. However, it cannot be used for all analyticalage results of those obtained in four serum samples from
healthy controls and kidney disease patients. methods because of a possible interference from PEG
[24]. The addition of PEG led to a very discreet decreaseTable 1 shows the results obtained for the serum con-
centrations of cystatin C and creatinine in kidney disease, in the concentration of recombinant human cystatin C
(Fig. 1), which suggests that PEG, at least at a finaland liver and kidney transplant patients. Table 2 shows
the residual concentrations of cystatin C after precipita- concentration of 120 g/L in the samples, does not produce
a significant analytical interference in the turbidimetriction with PEG (final concentration 120 g/L) in these
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Table 1. Serum cystatin C and creatinine concentrations in the groups of patients studied
Cystatin C mg/L Creatinine lmol/L
N MeanSEM Median Range MeanSEM Median Range
Kidney disease 87 4.580.21 4.97 0.84–8.48 510.9534.47 512.72 70.72–1175.7
Renal transplantation 182 3.070.13 2.38 1.16–10.27 289.9518.56 185.64 61.88–1264.12
Liver transplantation 71 2.620.11 2.49 1.13–5.22 129.958.84 106.08 53.04–380.12
Table 2. Cystatin C residual concentration after precipitation with
PEG 6000 (final concentration 120 g/L)
MeanSEM
N % Median Range
Kidney disease 87 86.80.68 87.6 70–100
Renal transplantation 182 84.80.52 84.2 70–100
Liver transplantation 71 88.20.87 88.0 71–100
method used. With this final concentration of PEG, as
used in the precipitation procedure of Levitt and Ellis
[18], we found a mean residual concentration for serum
cystatin C of 86% (Fig. 1), which may be due to a nonspe-
cific partial co-precipitation with other serum proteins
with a greater molecular mass. The results obtained for
amylase by other authors support this suggestion [18].
The results obtained for IgG and IgM, as shown in
Figure 1, may be superimposed on those of Luraschi et
al [21] and demonstrate the near-total precipitation of Fig. 2. Relationship between residual concentration of serum cystatin
these immunoglobulins for a final concentration of 120 C and post-surgery time in kidney () and liver () transplant patients
(r  0.098).g/L PEG. Unfortunately, those authors did not evaluate
the precipitation of IgA through the action of PEG [21],
whose residual concentration in the same test conditions
was, according to our results, approximately 30% (Fig. serum cystatin C concentrations with GFR within the
1). In any case, this fact does not appear to affect the reference limits, one of which was from a renal transplant
discriminatory capacity of the test decisively [18–22], nor, recipient and the other two with systemic sclerosis or
therefore, the interpretation of our results. rheumatoid arthritis [6]. An increased serum level of
No significant difference was found for the residual cystatin C was found in patients with autoimmune dis-
concentrations of cystatin C after precipitation with PEG eases [25], and a significant increase of cystatin C was
in the three groups of patients (Table 2), which present found in a group of patients with rheumatoid arthritis,
an analogous interindividual variation for this variable whereas creatinine did not differ significantly from the
(CV 8%). Bearing in mind the results obtained for healthy control group [26]. Because the grafted kidney
other serum components [18–22], the residual concentra- induces an antibody response it has been suggested re-
tion of cystatin C after precipitation with PEG was, in cently, without definitive proof, that there is an impaired
all cases, much higher than that expected in the case of filtration of cystatin C-immunoglobulin complexes in re-
there being complexes with immunoglobulins. There- nal transplant recipients [14]. However, we were not able
fore, it does not appear that in renal or liver transplants, to confirm the formation of these high molecular mass
circulatory cystatin C forms high-molecular-weight com- complexes in our patients, either those with renal or
plexes with immunoglobulins, regardless of the post- hepatic transplants or in the patients studied with rheu-
transplant time (Fig. 2). As a result, it was not possible matoid arthritis.
to confirm the hypothesis of Bo¨kemkamp et al that in In accordance with our experience, elevated cystatin
renal transplant patients cystatin C has an impaired glo- C concentrations with normal creatinine values in adult
merular filtration due to the formation of these macro- kidney transplant recipients after discharge from the hos-
complexes [14]. pital have been reported by other authors [27]. The re-
sults obtained three months after kidney transplantationNewman et al described three outliers with increased
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10. Risch L, Blumberg A, Huber A: Rapid and accurate assessmentby Le Bricon et al show that serum cystatin C underesti-
of glomerular filtration rate in patients with renal transplants using
mated GFR by approximately 14% with no false nega- serum cystatin C. Nephrol Dial Transplant 14:1991–1996, 1999
11. Le Bricon T, Thervet E, Benlakehal M, et al: Changes in plasmatives, but serum creatinine led to a gross overestimation
cystatin C after renal transplantation and acute rejection in adults.of GFR with 25% false negatives [12]. Its serum concen-
Clin Chem 45:2243–2249, 1999
trations are probably determined not only by GFR, but 12. Le Bricon T, Thervet E, Froissart M, et al: Plasma cystatin C is
superior to 24-h creatinine clearance and plasma creatinine foralso by additional factors that differ for cystatin C and
estimation of glomerular filtration rate 3 months after kidney trans-creatinine [28]. However, serum cystatin C appears to
plantation. Clin Chem 46:1206–1207, 2000
be a better marker of GFR than serum creatinine in 13. Bo¨kenkamp A, O¨zden N, Dieterich C, et al: Cystatin C and creati-
nine after successful kidney transplantation in children. Clin Ne-adults with normal to impaired kidney function [4–7, 28].
phrol 52:371–376, 1999Therefore, cystatin C determination may be useful in
14. Bo¨kenkamp A, Domanetzki M, Zinck R, et al: Cystatin C serum
kidney and liver transplant patients, although neither concentrations underestimate glomerular filtration rate in renal
transplant recipients. Clin Chem 45:1866–1868, 1999cystatin C nor creatinine reliably permits an estimation
15. Page MK, Bu¨kki J, Luppa P, Neumeier D: Clinical value of cystatinof the exact GFR.
C determination. Clin Chim Acta 297:67–72, 2000
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